These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 26369563)

  • 1. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
    Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiotropium Respimat inhaler and the risk of death in COPD.
    Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
    N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
    Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
    BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair
    Yildiz P; Bayraktaroglu M; Gorgun D; Secik F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR
    Wise RA; Calverley PM; Carter K; Clerisme-Beaty E; Metzdorf N; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
    Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
    Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
    Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
    Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.
    Wise R; Calverley PM; Dahl R; Dusser D; Metzdorf N; Müller A; Fowler A; Anzueto A
    NPJ Prim Care Respir Med; 2015 Nov; 25():15067. PubMed ID: 26540491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIOtropium Safety and Performance In Respimat
    Zhong N; Moon HS; Lee KH; Mahayiddin AA; Boonsawat W; Isidro MG; Bai C; Mueller A; Metzdorf N; Anzueto A
    Respirology; 2016 Nov; 21(8):1397-1403. PubMed ID: 27490162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV
    Calverley PMA; Mueller A; Fowler A; Metzdorf N; Wise RA
    Ann Am Thorac Soc; 2018 Feb; 15(2):200-208. PubMed ID: 28957643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.
    Wise RA; Anzueto A; Calverley P; Dahl R; Dusser D; Pledger G; Koenen-Bergmann M; Joseph E; Cotton D; Disse B
    Respir Res; 2013 Apr; 14(1):40. PubMed ID: 23547660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.
    Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
    Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
    PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
    Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
    Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
    Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
    Tang Y; Massey D; Zhong NS
    Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.